Modality
Bispecific Ab
MOA
AHRant
Target
SGLT2
Pathway
Autophagy
Pancreatic CaGastric Ca
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
~Apr 2021
→ ~Jul 2022
Phase 3
~Oct 2022
→ ~Jan 2024
NDA/BLA
Apr 2024
→ Sep 2030
NDA/BLACurrent
NCT04959605
566 pts·Pancreatic Ca
2024-04→2026-03·Recruiting
NCT06240068
669 pts·Gastric Ca
2024-09→2030-09·Not yet recruiting
1,235 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-231w agoPh3 Readout· Pancreatic Ca
2030-09-104.4y awayPh3 Readout· Gastric Ca
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2026-03-23 · 1w ago
Pancreatic Ca
Ph3 Readout
2030-09-10 · 4.4y away
Gastric Ca
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04959605 | NDA/BLA | Pancreatic Ca | Recruiting | 566 | CfB |
| NCT06240068 | NDA/BLA | Gastric Ca | Not yet recr... | 669 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 |